Although the monomeric GTPases RalA and RalB have been shown to regulate a variety of transcription factors, little is known regarding the differences or similarities in transcriptional programs regulated by RalA compared to RalB. Further, the association of these transcriptional pathways to human carcinogenesis and progression remains unclear. Here, we studied the role of RalA and/ or RalB in transcriptional regulation by combining short interfering RNA depletion of Ral with gene expression profiling via microarray in the human bladder cancer cell line, UMUC-3. A large number of genes were found to be similarly modulated in cells with RalA and RalB depletion, suggesting that RalA and RalB impinge on overlapping transcriptional signaling pathways. However, smaller sets of genes were modulated by depletion of RalA or RalB, indicating that these closely related proteins also regulate nonoverlapping transcriptional pathways. Computational analysis of upstream sequences of genes modulated by Ral depletion identified Ras-responsive element-binding protein (RREB)-1, as a putative Ral transcriptional target, which we verified experimentally. Importantly, as a group, Ral-regulated probe sets identified here were disproportionally represented among those differentially expressed as a function of human bladder transformation. Taken together, these data strongly suggest that Ral family members mediate both common and specific transcriptional programs that are associated with human cancer and identify RREB-1 as a novel transcriptional effector of Ral.
Introduction
Within the Ras family, RalA and RalB are closely related proteins with both overlapping and distinct functions (Feig, 2003) . Initially discovered as Ras homologs, they were shown to be regulated, at least in part, by Ras through its ability to stimulate RalGEFs such as RalGDS and Rlf (Wolthuis et al., 1998) . Although studies on rodent tumorigenesis suggested that RalGEFs, and by extension RalA and RalB, are not particularly tumorigenic (White et al., 1995) , recent results indicate more important roles for RalA and RalB in human cancer. For example, RalGEFs have been shown to be the most important effectors downstream of Ras in the transformation of human cells (Hamad et al., 2002) and RalA is a necessary component of Rasdriven tumorigenesis (Lim et al., 2005) . Conversely, RalB has been shown to be pro-migratory in human bladder and prostate cancer cells (Oxford et al., 2005) , and depletion of RalB via short interfering RNA (siRNA) has been shown to trigger apoptosis in many human cancer cell lines (Chien and White, 2003) . Both RalA and RalB have been shown to be pro-metastatic (Ward et al., 2001 ) and they appear to share an overlapping function in regulating cancer cell proliferation (Oxford et al., 2005) .
Ral proteins mediate cellular functions via a repertoire of effectors such as RalBP1, a GTPase-activating protein for Rac1 and Cdc42 (Jullien-Flores et al., 1995) , which also plays a role in the transport of glutathione conjugates (Awasthi et al., 2000) , Sec5 and exo84, components of the exocyst involved in regulated secretion (Moskalenko et al., 2003) , and the actin regulatory protein filamin (Ohta et al., 1999) . Through these, RalA and/or RalB regulate endocytosis of membrane receptors, exocytosis and delivery of polarized membrane proteins (Shipitsin and Feig, 2004) , cytoskeletal dynamics (Lebreton et al., 2004) , drug resistance (Awasthi et al., 2003) , motility (Gildea et al., 2002) and both anchorage-dependent and anchorage-independent proliferation (Chien and White, 2003) .
In addition, RalA and/or RalB have also been shown to regulate transcription factors such as nuclear factor k B (NF-kB), AP-1, FOXO4, HSF-1 and ZONAB (Camonis and White, 2005) . However, a fundamentally important question remains in the study of transcriptional regulation by Ral GTPases, namely whether RalA and RalB affect different transcriptional targets and whether this is carried out via the selective use of different transcription factors. Here, we sought to resolve this issue and to understand how transcriptional regulation contributes to RalA and RalB function in human cancer. These contributions were measured by selective depletion of RalA and/or RalB by siRNA knockdown in human bladder cancer cells and profiling the changes in gene expression following protein depletion. Common transcriptional components were identified and mechanistically validated.
Results
Expression profiles in response to protein knockdown indicate both similar and unique transcriptional networks downstream of Ral family members Because RalA and RalB both play important roles in human cancer and also regulate various transcription factors through mostly unknown mechanisms, we chose to investigate the contributions of RalA and RalB to overall transcriptional regulation. We chose to focus on the UMUC-3 human bladder cancer cell line because: (1) it is derived from an invasive tumor (Grossman et al., 1986) and maintains high in vitro migration (Oxford et al., 2005) and invasion (Wu et al., 2004) activities, (2) it has measurably active RalA and RalB (Oxford et al., 2005) , presumably, in part, due to harboring an activating K-Ras mutation (Jebar et al., 2005) and (3) we had previously shown in this cell line that siRNAmediated RalB depletion results in decreased cell motility and that depletion of both RalA and RalB impairs cell proliferation (Oxford et al., 2005) . We performed gene expression analysis using oligonucleotide arrays on UMUC-3 cells that had been transfected with siRNA specific for RalA, RalB or both RalA and RalB. Parallel transfections were processed for either protein or RNA. Figure 1a shows the effect of siRNA transfection on Ral protein levels, with both RalA-and RalB-specific duplexes reducing the expression of their respective targets B90% while having little effect on the expression of the other Ral protein, consistent with previous results (Oxford et al., 2005) . Also consistent was the effect of a single siRNA duplex targeting both RalA and RalB, which inhibited RalB expression B90% and RalA expression B65%. Figure 1b indicates that siRNA-mediated depletion of RalA and/or RalB proteins was accompanied by a parallel reduction in corresponding messenger RNA levels, as measured on the oligonucleotide array.
The numbers of differentially expressed probe sets in response to siRNA are summarized in Figure 1c . These data suggest the presence of unique transcriptional pathways regulated by RalA (62 and 15 genes, uniquely down-and upregulated, respectively, in response to RalA siRNA) and RalB (54 and 31 genes, uniquely down-and upregulated, respectively, in response to RalB siRNA). Interestingly, these data also indicate marked overlap in the set of genes regulated by RalA and RalB, with many probe sets showing significant expression changes in both RalA-and RalB siRNAtransfected cells. Furthermore, there is a larger number of probe sets, which show changes in expression only when cells are depleted of both RalA and RalB compared to each GTPase alone (547 vs 162), suggesting that, in many cases, unique signaling pathways may be triggered only when both RalA and RalB activity is altered. This indicates that functional interactions between several signaling pathways occur downstream of these two proteins. Table 1 shows the top 10 genes with the largest statistically significant positive (upregulated) or negative (downregulated) fold changes in response to siRNAmediated depletion of RalA, RalB or both RalA and RalB. Here also, the combination of both overlapping and unique contributions of RalA and RalB to transcriptional regulation is evident. Of the top 10 downregulated genes in response to RalA depletion, 6 were also significantly downregulated in response to RalB depletion. Conversely, 8 of the 10 most downregulated genes with RalB depletion were also downregulated with RalA depletion. For upregulated genes, 8 out of the top 10 for both RalA and RalB depletion were also significantly upregulated in the other case. Uniquely regulated, in response to RalA depletion, were solute carrier family 11, asparagine synthetase (both upregulated), eukaryotic translation initiation factor 4E binding protein 2 and interleukin 1 receptor accessory protein 1 (both downregulated). With RalB depletion, both ubiquitin-specific protease 18 and promyelocytic leukemia ubiquitin ligase were uniquely upregulated and natural killer cell transcript 4 was uniquely downregulated.
Given that depletion of RalA and/or RalB can trigger a wide range of phenotypes in cancer cells, we analysed the gene sets regulated in response to RalA and/or RalB siRNA for gene ontology classes. The results of gene ontology analysis are shown in Table 2 , with only one ontogeny class identified as statistically significant (Po0.001) in both the RalA-and RalB-regulated genes, and six somewhat overlapping ontology classes associated with RalA/B double knockdown.
RalA and RalB signal via different repertoires of transcription factors
Recently, tools have been developed to uncover putative transcription factor-regulatory pathways associated with changes in transcriptional profiles by looking for overrepresented transcription factor binding sites in the regulatory regions of genes with expression changes. We used such a tool called Computational Ascertainment of Regulatory Relationships (Inferred from Expression) or CARRIE (Haverty et al., 2004) , to analyse the genes regulated in response to Ral depletion. The most significant predictions by CARRIE of transcription factors regulated by Ral are shown in Table 3 .
Strikingly, the most significant prediction by CAR-RIE is that NF-kB may be regulated by RalB. It has previously been shown that both RalA and RalB regulate cyclin D1 expression in NIH 3T3 cells through activation of NF-kB (Henry et al., 2000) . This regulation occurs through unknown effectors, but does not appear to involve the Ral effectors RalBP1 or PLD1. To test the prediction that RalB regulates NF-kB in UMUC-3 bladder cancer cells, we generated UMUC-3 cells stably expressing a luciferase reporter gene under the control of an NF-kB-responsive promoter. Figure 2a shows that the luciferase activity of these cells was responsive to tumor necrosis factor a, consistent with this promoter being responsive to NF-kB (Henry et al., 2000) . When these cells were transfected with siRNA targeting RalA and/or RalB, only the cells with RalB siRNA showed a significant decrease (B30%) in luciferase activity (Figure 2b ). These data underscore the ability of CARRIE to accurately predict transcription factor pathways regulated in response to siRNA knockdown. To our knowledge, this is the first validation of this software program in mammalian cells. CARRIE also predicted that the Ras-responsive element-binding protein (RREB)-1 is regulated by the Ral GTPases. RREB-1 was discovered as a zinc-finger protein involved in mediating a Ras-driven differentiation program in a thyroid carcinoma cell line (Thiagalingam et al., 1996) . Given that both Ral and RREB-1 are regulated by Ras, we sought to determine the accuracy of the CARRIE prediction. We generated UMUC-3 cells stably expressing an RREB-1-driven luciferase reporter gene and showed that its expression was reduced by expression of an activated (G12V) HRas allele (Figure 3a) . This is consistent with RREB-1 being a transcriptional repressor of p16/INK4a (Zhang et al., 2003) . Figure 3b shows that transfection of siRNA targeting either RalB or RalA/B reduced luciferase expression in these RREB-1 reporter cells by 35-45%. In contrast, RalA siRNA appeared to have no effect on the RREB-luciferase reporter. To further test the regulation of RREB-1 by RalA and/or RalB, we transfected activated (G23V) versions of RalA and/or RalB into the RREB-luciferase reporter cells. Figure 3c shows that both activated RalA and RalB increased RREB-responsive luciferase activity by B40%, in both continuous serum and serum-starved conditions. These results validated the CARRIE prediction of RREB-1 regulation by RalA and RalB, thus revealing a novel Ral effector. In Figure 4a , the stimulation of RREB-1 activity by RalA and RalB is demonstrated in four other human cancer cell lines, including two bladder lines (UMUC-6, KU-7), PC-3 prostate cancer cells and HeLa cervical cancer cells. Also shown is the inhibition of RREB-1 activity by H-Ras in all the four cell lines.
Having elucidated the sets of genes regulated in response to RalA and/or RalB depletion in a human bladder cancer cell line, we sought to ground these in vivo by determining the extent to which the RalA/ RalB-driven transcriptional regulation contributes to human bladder cancer. To do this, we took advantage of 2 previously published data sets of gene expression profiling of human bladder tumors (Dyrskjot et al., 2004; Nicholson et al., 2004) , which, when combined, result in a cohort of 65 bladder tumors and 20 normal bladder epithelial samples profiled on HG-U133A GeneChips. From this cohort, we identified a total of 607 probe sets that were differentially expressed in human bladder cancer vs normal tissue. Of these 607 probe sets, we identified a total of 84 that were also regulated in response to RalA and/or RalB knockdown (Table 4A ). Further analysis showed that the overlaps between probe sets differentially regulated in bladder cancer and those regulated by RalA siRNA, RalB siRNA or RalA/B siRNA were, in all cases, statistically significant (Table 4b in Supplementary Materials). These results indicate that the Ral-regulated genes are overrepresented in the set of bladder cancer genes, highlighting the importance of Ral GTPases in human bladder cancer transformation.
Discussion
Recent studies on the roles of RalA and RalB in cancer have pointed toward an antagonistic relationship. For example, in bladder and prostate cancer cells, RalB stimulates migration, whereas RalA is antimigratory (Oxford et al., 2005) . In a defined model of Ras-driven tumorigenesis of human cells, RalA has been shown to promote transformation and tumor formation, while RalB has been shown to inhibit both (Lim et al., 2005) . RalB depletion was also shown to trigger apoptosis in certain cancer cell lines, and this was reversed by simultaneous depletion of RalA and RalB (Chien and White, 2003) . In light of these examples of antagonism between RalA and RalB, it is notable that expression of very few genes appeared to be regulated in an opposing manner by RalA vs RalB depletion (data not shown). This suggests that many, if not most, of the functional antagonism between RalA and RalB does not involve transcriptional regulation.
In contrast to the functional antagonism between RalA and RalB described above, depletion of RalA or RalB results in similar modulation of cellular transcription. In response to specific depletion, expression of many probe sets is modulated not only in the same direction, but also with roughly the same magnitude. One way of interpreting the large number of genes that are perturbed with the knockdown of both RalA and RalB (Figure 1c ) is that much of the ability to regulate transcription is shared. Thus, in the absence of one Ral, the other is still sufficient to modulate the relevant pathway(s). However, only the depletion of both Ral proteins results in additional changes in gene expression. The only ontology class associated with RalA depletion was that of 'genes regulated in response to stress' (Table 2 ). While we have previously shown that RalA depletion has no effect on motility or proliferation in bladder cancer cells, others have shown that both growth in soft agar and tumorigenic growth of Ras-transformed cells are inhibited by RalA depletion (Chien and White, 2003) . Growth under such suboptimal conditions may require stress responses that are mediated by RalA. With RalB depletion, the only significant ontology class was 'protein binding'. We have previously shown that RalB depletion results in impairment of motility and a reduction in actin stress fibers (Oxford et al., 2005) and others have shown that RalB depletion can trigger apoptosis of some cancer cells (Chien and White, 2003) . However, with such a broad ontology class as protein binding, it is difficult to ascertain the connections to cellular phenotype.
With the codepletion of RalA and RalB, gene ontology analysis uncovered six significant classes. Many of the ontology classes found in genes responding to RalA and RalB depletion, with the exception of 'protein binding', were unique and relevant to the phenotypes associated with RalA/B knockdown in these cells. For example, we have previously shown that RalA/B depletion in UMUC-3 bladder cancer cells inhibits proliferation (Oxford et al., 2005) , particularly in reduced serum conditions, without triggering apoptosis. Two of the gene ontology classes uncovered in these cells were 'regulation of growth' and 'regulation of cell growth'. This suggests that transcriptional regulation by RalA and RalB plays a significant role in generating this phenotype. The other two gene ontology classes, 'muscle development' and 'cytoskeletal protein binding', may be associated with the total loss of actin stress fibers in RalA/B-depleted cells (Oxford et al., 2005) .
We uncovered two novel transcription factor targets under Ral regulation in human bladder cancer cells. While RalA and RalB regulation of NF-kB in NIH 3T3 cells has previously been noted (Henry et al., 2000) , it appears that RalB is a more potent regulator of NF-kB than RalA in UMUC-3 cells. This discrepancy may reflect the differences between Ral/NF-kB activities in mouse (NIH3T3) vs human cells (UMUC-3), or reflect different mechanisms in cancer cells.
This study is also the first description of RREB-1 regulation by RalA/B. Given that RalGEFs are canonical effectors of Ras, and that Ras is known to regulate Ral activation through them, it may not be surprising that a Ras-responsive transcription factor such as RREB-1 is also regulated by RalA and/or RalB. The activation of Ras leading to Ral activation and RREB-1 regulation could either be positive or negative, depending on which gene is being studied in a specific cell type. Interestingly, we found that Ral activation appears to be opposing Ras activation in the regulation of RREB-1, in that a constitutively active H-Ras allele reduced the expression of an RREB-driven reporter gene. In contrast, constitutively active RalA and RalB increased the expression of the reporter construct. The relative contributions of Ras, RalA/B, as well as other Ras effectors to RREB-1 regulation warrant additional study. RREB-1 has been shown to regulate expression of the tumor suppressor p16/INK4a (Zhang et al., 2003) and has also been found in a histone-modifying corepressor complex called CtBP (Shi et al., 2003) , which has been implicated in tumorigenesis. Thus, the relationship between Ral GTPases and RREB-1 in human cancer will be an important component of further work.
Perhaps the most striking result of this study was the extent to which the genes regulated by RalA and/or RalB and the genes found to be differentially expressed in bladder tumors vs normal tissue overlapped. Nearly 14% (84/607) of the probe sets differentially expressed in human bladder cancer were also affected by Ral knockdown. Overrepresentation of Ral-regulated genes in a set of genes differentially expressed in human bladder cancer strongly suggests that transcriptional regulation by RalA and RalB contributes significantly to the development of human bladder cancer. However, because higher RalA and RalB activation states are thought to contribute to cancer formation and progression (Lim et al., 2005 (Lim et al., , 2006 , the siRNA-mediated approach we took may have uncovered different Ralregulated genes than those regulated by endogenously activated Ral in cancer cells. With Ral depletion triggering both increases and decreases in gene expression, dissecting out the complex relationships between RalA/B activation status and specific gene expression changes in bladder cancer progression will require further experiments. Meanwhile, among the genes which are differentially expressed in both bladder cancer and regulated by Ral depletion are vascular endothelial growth factor (VEGF), which plays a key role in tumor angiogenesis (Carmeliet, 2005) , and CD24, which we previously reported to be regulated by RalA/B (Smith et al., 2006) . The regulation of both VEGF and CD24 by RalA/B may represent an opportunity for therapeutic intervention. 
